Literature DB >> 20694740

Thromboxane-prostanoid receptor expression and antagonism in dextran-sodium sulfate-induced colitis.

Patsy R Carter1, Robert M McElhatten, Songlin Zhang, William S Wright, Norman R Harris.   

Abstract

OBJECTIVE: In the current study of murine colitis, the potential roles of thromboxane and the thromboxane-prostanoid (TP) receptor were investigated, in as much as thromboxane signaling has been implicated in human inflammatory bowel disease.
METHODS: Colitis was induced in C57BL/6 mice via ingestion of dextran sodium sulfate (DSS), with or without co-administration of the thromboxane synthase inhibitor ozagrel (25 mg/kg/day) or the TP receptor antagonist vapiprost (2.5 mg/kg/day).
RESULTS: Immunohistochemistry of colonic tissue demonstrated a DSS-induced increase in TP receptor expression, but not of thromboxane synthase. Moreover, tissue levels of the metabolite thromboxane B(2) were unchanged by DSS. Vapiprost, but not ozagrel, partially attenuated histologic signs of inflammation induced by DSS, with vapiprost allowing a smaller increase in colon weight per unit length than ozagrel. Vapiprost also tended to attenuate DSS-induced alterations in intestinal transit.
CONCLUSIONS: In summary, TP receptor antagonism was more effective than thromboxane synthase inhibition in alleviating DSS-induced colitis in mice.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20694740     DOI: 10.1007/s00011-010-0240-2

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  29 in total

1.  Temporal changes in colonic vascular architecture and inflammatory mediator levels in animal models of colitis.

Authors:  Caroline B Appleyard; Adrian Alvarez; William H Percy
Journal:  Dig Dis Sci       Date:  2002-09       Impact factor: 3.199

2.  Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo-controlled, double-blind, multi-centre clinical trial in active Crohn's disease.

Authors:  E Carty; D S Rampton; H Schneider; P Rutgeerts; J P Wright
Journal:  Aliment Pharmacol Ther       Date:  2001-09       Impact factor: 8.171

3.  Thromboxane synthase immunohistochemistry in inflammatory bowel disease.

Authors:  E Carty; C Nickols; R M Feakins; D S Rampton
Journal:  J Clin Pathol       Date:  2002-05       Impact factor: 3.411

4.  Participation of thromboxane and other eicosanoid synthesis in the course of experimental inflammatory colitis.

Authors:  J Vilaseca; A Salas; F Guarner; R Rodriguez; J R Malagelada
Journal:  Gastroenterology       Date:  1990-02       Impact factor: 22.682

5.  Characterization of prostanoid receptors mediating contraction of the gastric fundus and ileum: studies using mice deficient in prostanoid receptors.

Authors:  Y Okada; A Hara; H Ma; C Y Xiao; O Takahata; Y Kohgo; S Narumiya; F Ushikubi
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

6.  Hypersensitive prostaglandin and thromboxane response to hormones in rabbit colitis.

Authors:  R D Zipser; J B Patterson; H W Kao; C J Hauser; R Locke
Journal:  Am J Physiol       Date:  1985-10

7.  Apolipoprotein A-IV inhibits experimental colitis.

Authors:  Thorsten Vowinkel; Mikiji Mori; Christian F Krieglstein; Janice Russell; Fumito Saijo; Sulaiman Bharwani; Richard H Turnage; W Sean Davidson; Patrick Tso; D Neil Granger; Theodore J Kalogeris
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

8.  Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines.

Authors:  L A Dieleman; M J Palmen; H Akol; E Bloemena; A S Peña; S G Meuwissen; E P Van Rees
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

9.  Antiplatelet effect of Z-335, a new orally active and long-lasting thromboxane receptor antagonist.

Authors:  T Tanaka; Y Fukuta; R Higashino; R Sato; Y Nomura; Y Fukuda; S Ito; M Takei; T Kurimoto; H Tamaki
Journal:  Eur J Pharmacol       Date:  1998-09-11       Impact factor: 4.432

10.  Involvement of CPI-17 downregulation in the dysmotility of the colon from dextran sodium sulphate-induced experimental colitis in a mouse model.

Authors:  K Sato; S Ohkura; Y Kitahara; T Ohama; M Hori; M Sato; S Kobayashi; Y Sasaki; T Hayashi; T Nasu; H Ozaki
Journal:  Neurogastroenterol Motil       Date:  2007-06       Impact factor: 3.598

View more
  1 in total

1.  Decreased retinal blood flow in experimental colitis; improvement by eye drop administration of losartan.

Authors:  Megan N Watts; Randa S Eshaq; Patsy R Carter; Norman R Harris
Journal:  Exp Eye Res       Date:  2013-07-02       Impact factor: 3.467

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.